Pacira Pharmaceuticals (PCRX) Buy Rating Kept at Mizuho Securities; With $54.0000 Target; Last Week American Axle & Manufact. Holdings, Inc. (AXL) Coverage

July 25, 2017 - By Henry Gaston

Among 16 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 10 have Buy rating, 1 Sell and 5 Hold. Therefore 63% are positive. Pacira Pharmaceuticals has $113 highest and $31 lowest target. $62.82’s average target is 52.48% above currents $41.2 stock price. Pacira Pharmaceuticals had 35 analyst reports since July 28, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, December 21 by Mizuho. Canaccord Genuity maintained it with “Buy” rating and $6000 target in Monday, May 29 report. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) earned “Neutral” rating by Bank of America on Monday, August 3. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) earned “Buy” rating by Mizuho on Tuesday, May 3. On Friday, February 26 the stock rating was maintained by Brean Capital with “Buy”. As per Friday, July 14, the company rating was maintained by Jefferies. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) earned “Hold” rating by Brean Capital on Friday, July 1. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) earned “Buy” rating by Wedbush on Wednesday, May 24. The firm earned “Mkt Outperform” rating on Tuesday, January 5 by JMP Securities. The firm earned “Buy” rating on Tuesday, September 29 by Nomura.

Among 12 analysts covering American Axle & Manufacturing (NYSE:AXL), 6 have Buy rating, 2 Sell and 4 Hold. Therefore 50% are positive. American Axle & Manufacturing had 30 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of American Axle & Manufact. Holdings, Inc. (NYSE:AXL) earned “Neutral” rating by Citigroup on Monday, February 13. On Monday, January 25 the stock rating was maintained by Barclays Capital with “Equalweight”. RBC Capital Markets maintained American Axle & Manufact. Holdings, Inc. (NYSE:AXL) on Monday, August 3 with “Outperform” rating. CLSA downgraded the stock to “Underperform” rating in Friday, November 4 report. On Thursday, November 3 the stock rating was downgraded by Buckingham Research to “Neutral”. Northcoast initiated the shares of AXL in report on Tuesday, March 22 with “Neutral” rating. Deutsche Bank upgraded the shares of AXL in report on Thursday, December 1 to “Buy” rating. As per Tuesday, February 16, the company rating was maintained by RBC Capital Markets. On Tuesday, December 20 the stock rating was upgraded by RBC Capital Markets to “Outperform”. Bank of America downgraded American Axle & Manufact. Holdings, Inc. (NYSE:AXL) on Tuesday, June 21 to “Neutral” rating. See American Axle & Manufact. Holdings, Inc. (NYSE:AXL) latest ratings:

07/07/2017 Broker: RBC Capital Markets Rating: Buy New Target: $23.0000 Maintain
22/06/2017 Broker: Deutsche Bank Rating: Buy
21/06/2017 Broker: CLSA Rating: Buy New Target: $18.0000 Initiate
21/06/2017 Broker: Guggenheim Rating: Buy New Target: $18 Initiates Coverage On
08/05/2017 Broker: JP Morgan Rating: Overweight Reinitiate
13/02/2017 Broker: Citigroup Old Rating: Buy New Rating: Neutral Downgrade
13/02/2017 Broker: FBR Capital Rating: Underperform Maintain

Investors sentiment increased to 1.18 in Q4 2016. Its up 0.08, from 1.1 in 2016Q3. It increased, as 21 investors sold Pacira Pharmaceuticals Inc shares while 53 reduced holdings. 34 funds opened positions while 53 raised stakes. 38.95 million shares or 1.71% more from 38.30 million shares in 2016Q3 were reported. California State Teachers Retirement System has 0% invested in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 75,116 shares. Waddell And Reed Fincl Inc stated it has 561,680 shares. Century Companies accumulated 53,494 shares or 0% of the stock. Suffolk Mgmt, a New York-based fund reported 48,792 shares. Bank Of Montreal Can owns 83,156 shares. Bnp Paribas Arbitrage accumulated 1,168 shares. Partner Fund Mgmt Limited Partnership has invested 1.06% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Boothbay Fund Limited Co accumulated 10,078 shares or 0.11% of the stock. Northern Tru reported 459,304 shares or 0% of all its holdings. 170,700 were reported by Ubs Asset Americas. Barclays Public Limited Com holds 0.01% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) or 168,220 shares. Sphera Funds Mgmt Limited accumulated 50,000 shares. Broadfin Ltd Company invested 0.54% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Fmr Limited holds 1.75 million shares. Kcg Holdings holds 13,291 shares or 0.01% of its portfolio.

Since May 15, 2017, it had 0 buys, and 9 insider sales for $2.59 million activity. 768 Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares with value of $33,271 were sold by Braunstein Scott. Williams Kristen Marie sold $1.07 million worth of stock or 21,041 shares. The insider Scibetta James S sold 1,966 shares worth $85,169. 1,119 shares were sold by Riker Lauren Bullaro, worth $49,650 on Wednesday, June 7. $186,757 worth of stock was sold by STACK DAVID M on Monday, June 5. Jones James B also sold $33,227 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares.

About 2.29M shares traded or 390.00% up from the average. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has risen 12.40% since July 25, 2016 and is uptrending. It has underperformed by 4.30% the S&P500.

Analysts await Pacira Pharmaceuticals Inc (NASDAQ:PCRX) to report earnings on August, 3. They expect $-0.27 EPS, down 1,250.00% or $0.25 from last year’s $-0.02 per share. After $-0.38 actual EPS reported by Pacira Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -28.95% EPS growth.

Pacira Pharmaceuticals, Inc. is a holding company. The company has market cap of $1.69 billion. The Firm is a pharmaceutical firm focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. It currently has negative earnings. The Company’s lead product candidate is EXPAREL , which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia.

About 291,300 shares traded. American Axle & Manufact. Holdings, Inc. (NYSE:AXL) has risen 4.39% since July 25, 2016 and is uptrending. It has underperformed by 12.31% the S&P500.

American Axle & Manufacturing Holdings, Inc. makes, engineers, creates and validates driveline and drivetrain systems and related components and chassis modules for light trucks, sport utility vehicles, crossover vehicles, passenger cars and commercial vehicles. The company has market cap of $1.74 billion. The Company’s driveline and drivetrain systems include components that transfer power from the transmission and deliver it to the drive wheels. It has a 4.77 P/E ratio. The Company’s driveline, drivetrain and related products include axles, driveheads, chassis modules, driveshafts, power transfer units, transfer cases, chassis and steering components, transmission parts, electric drive systems and metal-formed products.